Zacks Investment Research upgraded shares of Oxford Immunotec Global (NASDAQ:OXFD) from a hold rating to a strong-buy rating in a research report sent to investors on Saturday, Zacks.com reports. The brokerage currently has $19.00 price target on the stock.
According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “
A number of other brokerages have also recently commented on OXFD. TheStreet cut Oxford Immunotec Global from a c- rating to a d+ rating in a research note on Monday, July 15th. Piper Jaffray Companies set a $20.00 price target on Oxford Immunotec Global and gave the company a buy rating in a research note on Wednesday, September 18th. ValuEngine upgraded Oxford Immunotec Global from a sell rating to a hold rating in a research note on Wednesday, September 25th. Cowen set a $20.00 price target on Oxford Immunotec Global and gave the company a buy rating in a research note on Tuesday, September 24th. Finally, BidaskClub upgraded Oxford Immunotec Global from a strong sell rating to a sell rating in a research note on Saturday, November 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Oxford Immunotec Global currently has an average rating of Buy and an average price target of $19.67.
Shares of Oxford Immunotec Global stock traded down $0.12 on Friday, hitting $16.69. The stock had a trading volume of 246,700 shares, compared to its average volume of 175,306. Oxford Immunotec Global has a twelve month low of $11.88 and a twelve month high of $18.60. The stock has a market cap of $441.36 million, a price-to-earnings ratio of 32.73 and a beta of 0.42. The company has a quick ratio of 12.76, a current ratio of 13.35 and a debt-to-equity ratio of 0.03. The business’s 50 day moving average is $15.67 and its two-hundred day moving average is $14.58.
Oxford Immunotec Global (NASDAQ:OXFD) last announced its quarterly earnings results on Tuesday, November 5th. The company reported $0.04 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.09. Oxford Immunotec Global had a return on equity of 15.75% and a net margin of 199.21%. The company had revenue of $21.20 million during the quarter, compared to analysts’ expectations of $20.23 million. During the same period in the prior year, the company earned ($0.13) EPS. Oxford Immunotec Global’s revenue was up 31.7% compared to the same quarter last year. As a group, equities analysts predict that Oxford Immunotec Global will post -0.17 earnings per share for the current fiscal year.
In related news, CEO Peter Wrighton-Smith sold 10,000 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $13.86, for a total transaction of $138,600.00. Following the completion of the transaction, the chief executive officer now directly owns 424,538 shares of the company’s stock, valued at approximately $5,884,096.68. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $16.45, for a total value of $49,350.00. Insiders sold a total of 63,000 shares of company stock valued at $972,650 over the last quarter. 4.21% of the stock is owned by corporate insiders.
Several hedge funds have recently modified their holdings of OXFD. Boston Advisors LLC raised its position in shares of Oxford Immunotec Global by 48.4% during the third quarter. Boston Advisors LLC now owns 127,744 shares of the company’s stock worth $2,124,000 after acquiring an additional 41,643 shares during the last quarter. Tocqueville Asset Management L.P. bought a new stake in Oxford Immunotec Global during the third quarter valued at $191,000. Oppenheimer & Co. Inc. boosted its position in Oxford Immunotec Global by 9.9% during the third quarter. Oppenheimer & Co. Inc. now owns 77,400 shares of the company’s stock valued at $1,287,000 after acquiring an additional 7,000 shares during the last quarter. California Public Employees Retirement System bought a new stake in Oxford Immunotec Global during the third quarter valued at $211,000. Finally, Quadrant Capital Group LLC boosted its position in Oxford Immunotec Global by 218.9% during the third quarter. Quadrant Capital Group LLC now owns 1,805 shares of the company’s stock valued at $29,000 after acquiring an additional 1,239 shares during the last quarter. 94.03% of the stock is owned by institutional investors.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
See Also: Retained Earnings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.